# **Special Issue**

# 20th Anniversary of Pharmaceuticals—Recent Advances in Metallodrug Design and Application

## Message from the Guest Editor

In recent times, cis-platin has often been used as a prime example of the serendipitous discovery of a platinum-based coordination complex for the treatment of a number of cancers, and analogs and derivatives of this important complex continue to be studied extensively. Zinc-, ruthenium-, arsenic-, copper- and gold-based complexes have all entered clinical trials as anti-cancer agents in the past few years. Other applications of metal-containing compounds in medicine include metal-macrocycle complexes for photodynamic therapy (PDT) and magnetic resonance imaging (MRI). In recognition of the 20th anniversary of Pharmaceuticals, the journal will publish a collection of both original research articles and reviews in a Special Issue highlighting recent advances in the design and application of metallodrugs in medicine and drug development. Topics include, but are not limited to, metal complexes as anti-cancer drugs, anti-viral and anti-bacterial therapeutics, photoactive compounds, ROS generators and anti-inflammatory agents.

### **Guest Editor**

Dr. Andrew Knight
Kemecatalytics, New Orleans, LA, USA

## Deadline for manuscript submissions

closed (28 May 2025)



## **Pharmaceuticals**

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/192491

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





## **Pharmaceuticals**

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



## **About the Journal**

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

### Editor-in-Chief

### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

## **Author Benefits**

### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

## **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

